# Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

> **NCT00299871** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 542 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** LIXISENATIDE (AVE0010)

## Key facts

- **NCT ID:** NCT00299871
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 542 (ACTUAL)
- **Last updated:** 2014-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299871, "Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00299871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*